![]() The forward-looking statements are not historical facts but reflect the author's current expectations regarding future results or events. PSYK will not be directly engaged in the manufacture, importation, possession, use, sale or distribution of psychedelic drugs or substances in either Canada or the U.S.Ĭertain statements herein may constitute a forward-looking statement, including those identified by the expression "expect" and similar expressions (including grammatical variations thereof). where applicable laws permit such activities. PSYK will passively invest in companies engaged in legal activities involving psychedelic drugs and substances in Canada and the U.S. Commercial activities involving psychedelic drugs and substances are permitted in Canada by parties who hold the required federal regulatory approvals and licences however, distribution and sales opportunities for psychedelic drugs and substances are heavily restricted at this time. Adult recreational use of psychedelic drugs and substances remains generally prohibited under the CDSA. The medical use of certain psychedelic drugs and substances remain illegal under Canadian federal law unless discretionary exemptions are granted under the CDSA, while a limited number of other drugs and substances may be prescribed by a health care practitioner to patients under their care. Psychedelic drugs and substances in Canada are primarily regulated under the Controlled Drugs and Substances Act (the "CDSA"), the Food and Drug Act and the regulations promulgated thereunder. Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. federal law, despite this prohibition, a limited number of states have either sought to decriminalize or authorize the medical use of certain psychedelic drugs and substances in limited. While the medical and adult use of certain psychedelic drugs and substances are generally prohibited under U.S. PSYK is expected to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances. There are risks associated with this product. Please read the relevant prospectus before investing. The prospectus contains important detailed information about the Horizons Exchange Traded Products. The Horizons Exchange Traded Products are not guaranteed, their values change frequently and past performance may not be repeated. Horizons ETFs has more than $17.5 billion of assets under management and 94 ETFs listed on major Canadian stock exchanges.Ĭommissions, management fees and expenses all may be associated with an investment in exchange traded products (the "Horizons Exchange Traded Products") managed by Horizons ETFs Management ( Canada) Inc. The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. is an innovative financial services company and offers one of the largest suites of exchange traded funds in Canada. ( Horizons ETFs Management ( Canada) Inc. ![]() The holdings of the Index, PSYK and its current portfolio weights are regularly updated and available at About Horizons ETFs Management ( Canada) Inc. At those points, all stocks eligible for inclusion are generally re-weighted by their respective float market capitalization. Rebalancing of the North American Psychedelics Index occurs each calendar quarter. PSYK seeks to replicate, to the extent possible and net of expenses, the performance of the Index. ![]() In order for a stock to be eligible for the fast-entry inclusion, it must have a float market capitalization in excess of CAD $50 million.įollowing their fast entry additions into the Index, Mindset Pharma and Novamind have been, or will be, added as constituent holdings of PSYK. One of the innovative features of the Index is that it has a "Fast Entry" rule, which allows the Index, and by extension, PSYK, to add new stocks shortly after they become publicly available, assuming they qualify for inclusion. The Index is designed to provide diversified exposure to the psychedelics industry, at weights that can easily and cost effectively be replicated, while at the same time reflecting the evolution of the industry in a timely fashion. The Index is designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry. (" Novamind") have been included as fast entry additions to the North American Psychedelics Index (the " Index"), which is the underlying index of the Horizons Psychedelic Stock Index ETF (" PSYK"). (" Horizons ETFs") is announcing that Mindset Pharma Inc. 19, 2021 /CNW/ - Horizons ETFs Management ( Canada) Inc.
0 Comments
Leave a Reply. |